1. Home
  2. RBCAA vs AGIO Comparison

RBCAA vs AGIO Comparison

Compare RBCAA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Republic Bancorp Inc.

RBCAA

Republic Bancorp Inc.

HOLD

Current Price

$91.21

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$36.97

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBCAA
AGIO
Founded
1974
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
1998
2013

Fundamental Metrics

Financial Performance
Metric
RBCAA
AGIO
Price
$91.21
$36.97
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $46.00
AVG Volume (30 Days)
74.8K
★ 1.0M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
★ 2.15%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.77
N/A
Revenue
★ $417,495,000.00
$43,011,000.00
Revenue This Year
N/A
$229.47
Revenue Next Year
$3.20
$94.99
P/E Ratio
$119.76
★ N/A
Revenue Growth
★ 8.50
N/A
52 Week Low
$63.97
$22.24
52 Week High
$102.22
$46.00

Technical Indicators

Market Signals
Indicator
RBCAA
AGIO
Relative Strength Index (RSI) 45.70 66.86
Support Level $88.88 $32.17
Resistance Level $93.78 $44.09
Average True Range (ATR) 2.00 1.43
MACD 0.07 0.73
Stochastic Oscillator 47.75 91.70

Price Performance

Historical Comparison
RBCAA
AGIO

About RBCAA Republic Bancorp Inc.

Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: